A Randomized, Open-label, Multicenter Phase II Clinical Trial of Rovadicitinib in the Treatment of Third-line and Subsequent Moderate to Severe Chronic Graft-versus-host Disease (cGVHD).
Sponsor study identifier
interventional
65
1 country
12
Study Start
May 7, 2024
Actual (reported)Primary Completion
November 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 4, 2024
Actual (reported)March 8, 2024
Actual (reported)May 7, 2024
Actual (reported)November 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
May 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Objective response rate (ORR) at 24 weeks
Percentage of subjects with an overall response of all evaluable organs as complete response (CR) or partial response (PR).
Up to 24 weeks
Best objective response rate (BOR)
Up to 96 weeks
Duration of response (DOR)
Up to 96 weeks
Failure-free survival (FFS)
Up to 96 weeks
Incidence rate of malignancy relapse or recurrence
Up to 96 weeks
Non relapse mortality
At least 96 weeks
TQ05105 Tablets administered twice-daily. 28 days as a treatment cycle.
Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Anhui Provincial Hospital
Hefei, Anhui, 230001, China
The 940th hospital of joint logistics support force of Chinese people's liberation army
Lanzhou, Gansu, 730050, China
First Submitted
March 4, 2024
First Posted
March 8, 2024
Study Start
May 7, 2024
Actual (reported)Primary Completion
November 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Anlotinib Treatment in Steroid Depenent/Refractory cGVHD
Contact the study team to confirm eligibility.
Guangzhou First People's Hospital
Guangzhou, Guangdong, 510180, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
Xiangyang Central Hospital
Xiangyang, Hubei, 441021, China
Tai'an Central Hospital
Taian, Shangdong, China
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shannxi, 710299, China
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
The Affiliated People's Hospital of Ningbo University
Ningbo, Zhejiang, 315040, China
Study Completion
May 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 26, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: